The Treatment of Chilblains

Chilblains, known medically as pernio or perniosis, are a common yet
frequently misunderstood cold-related condition affecting the skin.
Characterised by painful, itchy, and inflamed patches on the extremities —
most often the toes, fingers, ears, and nose — chilblains develop in
response to repeated exposure to cold, damp conditions rather than to
freezing temperatures alone. Unlike frostbite, which involves actual tissue
freezing, chilblains arise from an abnormal vascular response to cold: small
blood vessels near the skin surface constrict when chilled and then dilate
too rapidly upon rewarming, causing localised inflammation and fluid
leakage into surrounding tissue. Understanding the range of available
treatments — from simple home remedies to pharmacological
interventions — is essential for managing the condition effectively and
preventing its recurrence.

Understanding the Condition
Before exploring treatments, it is useful to appreciate the clinical
picture of chilblains. They typically appear within hours of cold exposure
as reddish or purplish, swollen, and tender lesions. The affected skin may
blister, crack, or ulcerate in severe cases, creating a risk of secondary
infection. The condition predominantly affects women, the elderly, and
individuals with a low body mass index, though it can occur at any age.
People with certain underlying conditions — including lupus
erythematosus, Raynaud’s phenomenon, and connective tissue disorders —
are at elevated risk of developing a chronic or more severe form of
perniosis. Recognising whether chilblains are idiopathic (primary) or
secondary to another condition is an important first step, as this influences
both treatment selection and prognosis.

General Measures and Prevention
The cornerstone of chilblain management is prevention through
behavioural and environmental modification. Patients are strongly advised to keep the entire body warm, not just the extremities, as generalised
warmth reduces the vasoconstrictive response that triggers the condition.
Wearing insulated, moisture-wicking socks and gloves, avoiding damp
footwear, and limiting prolonged exposure to cold and wet conditions are
fundamental preventive strategies. When returning indoors from the cold,
gradual rewarming is critical; immersing cold hands or feet in hot water
should be avoided, as the sudden temperature change can worsen the
inflammatory cascade. Instead, the affected areas should be allowed to
warm slowly at room temperature. Regular gentle exercise to improve
peripheral circulation, smoking cessation (as nicotine impairs vascular
function), and maintaining a healthy body weight are all recommended to
reduce susceptibility.

Topical Treatments
For mild to moderate chilblains, topical therapies form the first line of
symptomatic relief. Emollients and moisturising creams help to soothe dry,
cracked skin and restore the barrier function, reducing the risk of
secondary bacterial infection. Calamine lotion has traditionally been used
to relieve itching and provide a mild anti-inflammatory effect. Topical
corticosteroids, such as hydrocortisone cream, may be prescribed to reduce
localised inflammation and alleviate discomfort in the short term; however,
their prolonged use should be avoided due to the risk of skin thinning.
Topical diltiazem, a calcium channel blocker available in some
formulations, has been used with some benefit in promoting local
vasodilation and reducing symptom severity. In cases where the skin has
broken down or ulceration has occurred, antiseptic dressings or topical
antibiotics may be necessary to prevent or treat infection.

Pharmacological Interventions
When chilblains are recurrent, severe, or unresponsive to conservative
measures, systemic pharmacological treatment may be warranted. The
most widely used and well-evidenced oral therapy is nifedipine, a
dihydropyridine calcium channel blocker. Nifedipine works by relaxing the
smooth muscle of blood vessel walls, promoting vasodilation and
improving peripheral blood flow. Studies have shown that both
prophylactic and therapeutic use of nifedipine significantly reduces the
frequency, duration, and severity of chilblain episodes. It is typically administered at a dose of 20-60 mg per day and is generally well tolerated,
though side effects such as headache, flushing, ankle oedema, and
hypotension can occur. Other vasodilatory agents, including amlodipine
and diltiazem, have been used as alternatives when nifedipine is not
tolerated. Pentoxifylline, a drug that improves blood rheology and
microcirculatory flow, has also shown promise in some studies, particularly
for perniosis associated with connective tissue disease.

Treatment of Secondary and Lupus-Related Chilblains
Chilblain lupus erythematosus represents a distinct and more chronic
form of the condition, in which the skin lesions share features of both
perniosis and cutaneous lupus. Management of this subtype requires a
more targeted approach. In addition to the vasodilatory agents described
above, hydroxychloroquine — an antimalarial drug with
immunomodulatory properties — is frequently prescribed and has
demonstrated efficacy in reducing lesion frequency and severity. In
refractory cases, systemic immunosuppressants such as methotrexate,
dapsone, or mycophenolate mofetil may be considered, always under
specialist supervision. It is essential that secondary causes are identified and
treated in parallel, as addressing the underlying condition often leads to
significant improvement in skin manifestations.

Emerging and Adjunctive Therapies
Research into chilblain treatment continues to evolve. Phototherapy
using narrow-band ultraviolet B (UVB) light has been explored as an
adjunctive treatment in chronic cases, with some evidence of benefit in
reducing inflammation. Sympathectomy — a surgical or chemical
procedure that severs sympathetic nerve supply to reduce vasospasm —
has been employed in severe, refractory cases, though it is rarely required.
Interest has also grown in the use of topical minoxidil, which promotes
vasodilation and has shown anecdotal benefit in small case series. The
COVID-19 pandemic brought renewed scientific attention to chilblain-like
lesions observed in some patients, sparking further investigation into the
underlying vascular and immunological mechanisms that may inform
future therapeutic targets.

Chilblains, while rarely dangerous, can be significantly debilitating and
are prone to recurrence if the underlying risk factors are not addressed.
Effective management rests on a combination of preventive strategies,
symptomatic topical care, and, where necessary, systemic
pharmacotherapy. Nifedipine remains the pharmacological gold standard
for recurrent or severe disease, while secondary causes must always be
considered and treated appropriately. Patient education about cold
avoidance, appropriate clothing, and gradual rewarming is paramount.
With a thoughtful, individualised approach — blending practical lifestyle
advice with evidence-based medication — the vast majority of those
affected can achieve meaningful symptom relief and reduce the impact of
this cold-weather condition on their daily lives.